On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients and talk about what it’s been like to work with each other in a business, given that they Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.
On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients and talk about what it’s been like to work with each other in a business, given that they are brothers. Martin R. Low also discusses what it’s been like for him to run a pharma company, since his prior expertise ranges a variety of other industries outside of pharma.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.